- Home
- VIVS vs EVOK Comparison
VIVS vs EVOK Comparison
Compare VIVS & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- EVOK
- Stock Information
- Founded
- VIVS 2007
- EVOK 2007
- Country
- VIVS United States
- EVOK United States
- Employees
- VIVS N/A
- EVOK N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- EVOK Health Care
- Exchange
- VIVS Nasdaq
- EVOK Nasdaq
- Market Cap
- VIVS 8.1M
- EVOK 7.6M
- IPO Year
- VIVS N/A
- EVOK 2013
- Fundamental
- Price
- VIVS $2.28
- EVOK $10.69
- Analyst Decision
- VIVS
- EVOK
- Analyst Count
- VIVS 0
- EVOK 0
- Target Price
- VIVS N/A
- EVOK N/A
- AVG Volume (30 Days)
- VIVS 1.4M
- EVOK 227.3K
- Earning Date
- VIVS 11-12-2025
- EVOK 11-07-2025
- Dividend Yield
- VIVS N/A
- EVOK N/A
- EPS Growth
- VIVS N/A
- EVOK N/A
- EPS
- VIVS N/A
- EVOK N/A
- Revenue
- VIVS $142,000.00
- EVOK $12,794,859.00
- Revenue This Year
- VIVS $42.38
- EVOK $57.38
- Revenue Next Year
- VIVS $15.42
- EVOK $59.57
- P/E Ratio
- VIVS N/A
- EVOK N/A
- Revenue Growth
- VIVS 94.52
- EVOK 70.02
- 52 Week Low
- VIVS $1.41
- EVOK $1.94
- 52 Week High
- VIVS $21.96
- EVOK $10.79
- Technical
- Relative Strength Index (RSI)
- VIVS 43.02
- EVOK 84.45
- Support Level
- VIVS $2.05
- EVOK $4.50
- Resistance Level
- VIVS $3.20
- EVOK $10.79
- Average True Range (ATR)
- VIVS 0.31
- EVOK 0.28
- MACD
- VIVS -0.02
- EVOK 0.70
- Stochastic Oscillator
- VIVS 20.00
- EVOK 98.18
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.